Piper Sandler Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $67
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Yasmeen Rahimi has initiated coverage on Sagimet Biosciences (NASDAQ:SGMT) with an Overweight rating and a price target of $67.
August 08, 2023 | 9:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Sagimet Biosciences with an Overweight rating and a price target of $67, which could positively impact the stock.
Analyst ratings and price targets can significantly influence a stock's performance. An Overweight rating suggests that the analyst believes the stock will outperform its industry in the near term. The price target of $67 indicates a significant upside potential from the current price, which could attract investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100